标签模块

标签模块

副标题

About us


    "If the IVD industry doesn't change, we will change the IVD industry!" As a pioneer and leader in the research and development of biomolecules for many years, Dr. Ming Liu, the founder/chief scientist of BioNC, has always had the long-cherished wish to empower the IVD industry with the research results of antibody engineering.

    At present, BioNC has grown into a rare and innovative IVD raw material company with a full set of upstream R&D "source code" in China, and has formed two operating entities, Beijing BioNC Co. Ltd. and BioNC (Ningbo) Biotechnology Co. BioNC has a core team of 23 doctors and masters, and a team of more than 10 renowned experts including academicians from the Chinese Academy of Sciences and visiting scholars from Harvard University, and has established joint laboratories with many universities and research institutes at home and abroad.

    BioNC is mainly engaged in the R&D and production of high quality IVD antibodies and antigenic raw materials, with user needs as the guide and the core competitiveness of continuous leading antibody discovery technology, actively building an independent innovation system combining academia, research, production and application, and aspiring to be the redefiner and long-term leader of high quality IVD raw materials in China. We have built a trinity of "artificial intelligence+" antibody R&D technology platform of discovery, optimization and evaluation, especially in the areas of antibody affinity maturation, humanization transformation, stability transformation, etc., and polished the "three magic weapons" technology with high barriers. Our core products cover almost all IVD raw materials, involving nearly 1000 kinds of high-quality IVD antibodies and antigen raw materials, which are widely used in various application scenarios such as chemiluminescence, immunofluorescence, lateral chromatography, immunohistochemistry and multi-factor assay. As of June 2022, IVD antigens and antibodies from BioNC have been used by industrial or scientific users in 43 countries.  

    The code of action of BioNC to participate in building a community for human health is to guard the righteousness and to respond to the needs of the people. In the future, BioNC will continue to provide the best quality IVD raw material products and services with its innovative technology system, and provide health protection for China and the world in the midst of the unprecedented changes of the century!

公司历程3329

公司历程3329

副标题

2017
2018
2019
2020
2021

In April 2017, Dr. Liu Ming, the founder of BioNC, first established the ambition to do something for the import substitution of IVD raw materials when he visited the United States.

In March 2018, the first carrier of BioNC, Beijing BioNC Biotech Co., Ltd. was officially established. In October 2018, the founding team of BioNC was all in place.

In March 2019, the three major technical platforms of antibody affinity maturation, humanization modification and stability modification were completed. In September 2019, the first order of 100mg grade IVD antibody was completed.

In January 2020, Baxinan established the COVID-19 Task Force. In March 2020, the first neo-coronavirus monoclonal antibody, BN9, was launched, and the antibody later became BioNC's first 10g-class hot product to be shipped. In May 2020, Baxinyl's COVID-19 quality control antibody was selected as a standard by China Academy of Metrology. In October 2020, the project team of "Next-generation IVD raw material R&D and production platform", led by Dr. Liu Ming, was officially shortlisted in the "Xiongzhen talents" plan of Ningbo City. In November 2020, Ningbo BioNC Biotech Co., Ltd. was officially established.

In March 2021, Dr. Liu Ming was invited to participate in the "Bright-Test - The 4th In Vitro Diagnostics Young Entrepreneurs Forum" hosted by the Medical Testing Industry Branch of the National Health Industry Enterprise Management Association.
+86 01089359064
CS@bionc.com.cn
Technical Support
 
 
——————
Contact No.
13581724949